RTS,S/AS01 Malaria Vaccine - The Next Step for a Developing Country.
作者信息
Zehra Asmat, Syed Bushra, Masood Fareeha
机构信息
Dow University of Health Sciences, Baba-e-Urdu Road Karachi, Pakistan.
出版信息
J Prev Med Hyg. 2022 Apr 26;63(1):E130-E131. doi: 10.15167/2421-4248/jpmh2022.63.1.2379. eCollection 2022 Mar.
Abstract
摘要
相似文献
1
RTS,S/AS01 Malaria Vaccine - The Next Step for a Developing Country.RTS,S/AS01疟疾疫苗——发展中国家的下一步举措
J Prev Med Hyg. 2022 Apr 26;63(1):E130-E131. doi: 10.15167/2421-4248/jpmh2022.63.1.2379. eCollection 2022 Mar.
2
[Potential challenges for large-scale uses of RTS, S/AS01 vaccine in malaria-endemic areas].[疟疾流行地区大规模使用RTS,S/AS01疫苗的潜在挑战]
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2022 Jan 10;33(6):553-554. doi: 10.16250/j.32.1374.2021249.
3
Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.加纳儿童按照不同方案接种 RTS,S/AS02D 和 RTS,S/AS01E 疟疾候选疫苗的随机对照试验
PLoS One. 2009 Oct 2;4(10):e7302. doi: 10.1371/journal.pone.0007302.
4
[Development and application of the world's first malaria subunit vaccine RTS, S/AS01].[世界首个疟疾亚单位疫苗RTS，S/AS01的研发与应用]
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2022 Jan 8;33(6):557-559. doi: 10.16250/j.32.1374.2021250.
5
Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.RTS,S/AS01E 疟疾疫苗候选者在 5 至 17 个月大的肯尼亚和坦桑尼亚儿童中的安全性。
PLoS One. 2010 Nov 29;5(11):e14090. doi: 10.1371/journal.pone.0014090.
6
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.RTS,S/AS01 疟疾疫苗在婴幼儿中的安全性特征：撒哈拉以南非洲地区 III 期随机对照试验的补充数据。
Hum Vaccin Immunother. 2019;15(10):2386-2398. doi: 10.1080/21645515.2019.1586040. Epub 2019 Apr 23.
7
The Advanced Development Pathway of the RTS,S/AS01 Vaccine.RTS,S/AS01疫苗的先进研发途径。
Methods Mol Biol. 2019;2013:177-187. doi: 10.1007/978-1-4939-9550-9_13.
8
Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites.RTS,S/AS01疟疾疫苗接种后18个月的疗效和安全性：在11个非洲地点对儿童和幼儿进行的3期随机对照试验
PLoS Med. 2014 Jul 29;11(7):e1001685. doi: 10.1371/journal.pmed.1001685. eCollection 2014 Jul.
9
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.RTS,S/AS01E 候选疟疾疫苗与扩大免疫规划疫苗联合接种的安全性和有效性：一项随机、开放标签、2 期临床试验的 19 个月随访。
Lancet Infect Dis. 2011 Oct;11(10):741-9. doi: 10.1016/S1473-3099(11)70100-1. Epub 2011 Jul 22.
10
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.RTS,S/AS01 疟疾疫苗在非洲儿童中进行的 3 期临床试验的初步结果。
N Engl J Med. 2011 Nov 17;365(20):1863-75. doi: 10.1056/NEJMoa1102287. Epub 2011 Oct 18.
本文引用的文献
1
[The current status of the resistance of malaria pathogens to antimalarials].[疟疾病原体对抗疟药的耐药性现状]
Med Parazitol (Mosk). 2014 Jul-Sep(3):51-7.
2
Chloroquine resistance in Pakistan and the upsurge of falciparum malaria in Pakistani and Afghan refugee populations.巴基斯坦的氯喹耐药性以及巴基斯坦和阿富汗难民群体中恶性疟原虫疟疾的激增。
Ann Trop Med Parasitol. 1997 Sep;91(6):591-602. doi: 10.1080/00034989760680.
3
Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei.注射经X射线照射的伯氏疟原虫子孢子产生的保护性免疫。
Nature. 1967 Oct 14;216(5111):160-2. doi: 10.1038/216160a0.
Zotero 插件